

**BBCIC**Biologics & Biosimilars  
Collective Intelligence Consortium**QUARTERLY**

## We are excited to present BBCIC's refreshed mission statement:

*To generate reliable real-world evidence that examines the safety and effectiveness of biologics in order to improve public health.*

### A Note from the Executive Director

I hope you had some well-deserved time to relax and recharge over the holidays! 2020 was a challenging year for the world, and I can't help but see the light that 2021 will bring on the horizon. We have all had to test our perseverance and stamina, and I'm proud of the accomplishments and contributions by the BBCIC community to continue pushing our research forward.

[Read the full letter.](#)

### Current Research

#### G-CSF Comparative Safety and Effectiveness

Our partners at [STATLOG](#) have nearly completed preparing the ad hoc programming needed and we anticipate initial data will be compiled from the BBCIC Research Partners in March and April.

We are on schedule for data analysis and a draft report by the end of summer!

#### Insulins Utilization Analysis

Specifications are undergoing minor revisions to re-run this study to augment data that were collected a year ago as part of our effort to produce repeatable analyses to increase our longitudinal understanding of insulin use and select outcomes in our patient population.

### In this Issue

- A Note from the Executive
- Current Research
- Research Plans
- Publications
- Abstracts Tracker
- Planned Publications
- Abstracts
- Research Timeline

### Planned Publications

#### Anticipated Manuscript Submissions

- G-CSF Scoping Review
- Oncology Data Feasibility
- G-CSF CER Methods/Protocol
- Trastuzumab Scoping

## Oncology Data Fitness Workgroup

A report describing the findings of the workgroup and recommended next steps for BBCIC in our efforts to enrich our existing data capabilities to better answer clinical effectiveness questions in oncology.

## Trastuzumab Utilization Analysis

Data analysis is underway for our first look at utilization patterns and characteristics of patients in the BBCIC DRN who were treated with trastuzumab.

## Bevacizumab Utilization Analysis

The study design is in development and we anticipate results for the utilization and treatment patterns, and characteristics of patients with bevacizumab for both cancer (on-label) and ophthalmology (off-label) indications.

## Research Plans

### Trastuzumab Comparative Safety and Effectiveness

As the first priority determined by the BBCIC Science Committee, we will build off of the work by the oncology data feasibility workgroup to plan for our data needs, and to begin formulating a study plan.

### Switching Patterns in Rheumatoid Arthritis

A group will be convened to define our specific research question, building on the work and recommendations from the Switching Workgroup, to design a study to evaluate treatment patterns, medication switching, and selected outcomes in patients treated for rheumatoid arthritis

## Publications

Three manuscripts have been published so far in 2021! Our loooooong wait for peer review in 2020 is paying off in 2021! Congratulations!

### BBCIC Research Network Analysis of First-Cycle Prophylactic G-CSF Use in Patients Treated with High Neutropenia Risk Chemotherapy

- Pamala A. Pawloski, Cara L. McDermott, James H. Marshall, Vanita Pindolia, Catherine M. Lockhart, Catherine A. Panozzo, Jeffrey S. Brown, Bernadette Eichelberger.

*J Natl Compr Canc Netw. In Press.*

### Patient Characteristics and Utilization Patterns of Short-Acting Recombinant Granulocyte Colony-Stimulating Factor (G-CSF) Biosimilars Compared to Their Reference Product

Review\*\*

- Trastuzumab Utilization Analysis
- Bevacizumab Scoping Review – Breast Cancer\*\*
- Bevacizumab Scoping Review – AMD\*\*
- Bevacizumab Utilization Analysis
- Rituximab scoping review\*
- Anti-Inflammatories scoping review\*
- G-CSF CER Final Results

\*University of North Carolina School of Pharmacy Student Project

\*\*University of Utah Fellow Project

## Abstracts

Two BBCIC abstracts have been accepted for poster presentation at AMCP 2021:

- Utilization patterns and characteristics of patients treated with the originator and follow-on insulin

- Aaron B. Mendelsohn, James Marshall, Cara L. McDermott, Pamala A. Pawloski, Jeffrey S. Brown, Catherine M. Lockhart.

[Drugs – Real World Outcomes](#). Online First.  
doi:10.1007/s40801-021-00228-9.

**Utilization Patterns and Characteristics of Users of Biologic Anti-Inflammatory Agents in a Large, US Commercially Insured Population**

- Aaron B. Mendelsohn, Young Hee Nam, James Marshall, Cara L. McDermott, Bharati Kochar, Michael D. Kappelman, Jeffrey S. Brown, Catherine M. Lockhart

[Pharmacology Research & Perspectives](#). 2021;9.e00708

glargine in the United States.

Presenting author Young Hee Nam, PhD, Harvard Pilgrim Healthcare Institute post-doctoral fellow.


- Characterization of real-world data sources to support observational studies of biologics, including biosimilars in oncology. [Bronze medal winner].

Presenting author Ryan M. Seals, ScD, epidemiologist at Optum Life Sciences.

**Research Timeline**

[View BBCIC's 2021 Research Timeline](#)

**Abstract**



2020 Biologics and Biosimilars Collective Intelligence Consortium (BBCIC) | [bbcic.org](http://bbcic.org)

Address  
 675 N Washington Street  
 Suite 220  
 Alexandria, VA 22314

[Unsubscribe me from this email.](#)